This appraisal was discussed by the appraisal committee on 5 October 2021. Following the meeting, further work was required before the committee could make its recommendation. The appraisal is progressing and further updates will be provided on this web page in due course. Until this appraisal is completed, the recommendations in TA528 remain in place and niraparib continues to be available through the Cancer Drugs Fund where eligible patients can receive this treatment without change.